Thursday, Jazz Pharmaceuticals plc JAZZ released topline results from the Phase 2b trial evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET).
Jazz Pharmaceuticals said on Thursday its experimental drug to treat a neurological condition that causes involuntary and rhythmic shaking failed to meet the main goal in a mid-stage study.
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
If the market's dramatic shifts this year leave you discombobulated, you're not alone. But, despite widespread overvaluation across a range of tech stocks, plenty of cheap blue-chip stocks are ready to offer the portfolio stability we're all desperately seeking.